| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.44B | -22.3% |
| Gross profit | ¥0.06B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.02B | -41.9% |
| Gross margin | 13.8% | Net margin 5.2% |
| Revenue Q/Q | -28.5% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.38B | 86.2% |
| R&D | ¥0.02B | 4.5% |
| SG&A | ¥0.04B | 8.6% |
| Tax & other | ¥0.00B | 0.9% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
维宏股份 ・ 新美星 ・ 金冠股份 ・ 雪榕生物 ・ 中亚股份 ・ 恒实科技 ・ 友讯达 ・ 三德科技 ・ 久之洋 ・ 海波重科 ・ 新迅达 ・ 新光药业
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies